Key Takeaways
- • Primo Capital has launched Primo Biotech Lazio, a dedicated venture capital fund focused on biotechnology investments, established in partnership with the Lazio Region to support biotech innovation in central Italy.
- • The fund is part of Primo Capital's multi-fund investment structure, which now includes specialized vehicles across digital, space, climate, and health sectors with over €500 million in committed assets under management.
- • Primo Capital's biotech strategy complements its existing healthcare-focused Primo Health fund (target: €120 million for SME investments) and positions the firm as a vertically integrated investor across life sciences and digital health technologies.
- • The Lazio Region partnership indicates regional government support for venture capital development in the biotech sector, aligning with Italy's broader initiative to build innovation ecosystems outside traditional financial centers like Milan.
Summary
Primo Capital, a Milan-based venture capital firm, has announced the launch of Primo Biotech Lazio, a new venture capital fund dedicated to biotechnology investments. The fund was established through a partnership with the Lazio Region, reflecting a strategic initiative to develop the biotech sector in central Italy. This launch expands Primo Capital's existing portfolio of specialized investment funds across multiple technology verticals.
Primo Capital operates as a multi-fund investment vehicle with over €500 million in committed assets. The firm's investment strategy spans four primary sectors: digital, space, climate, and health. The Primo Biotech Lazio fund represents the company's targeted expansion into dedicated biotechnology investment, complementing its existing Primo Health fund, which focuses on healthcare technology and small-to-medium enterprises with a €120 million target. This structure allows Primo Capital to address the life sciences ecosystem through both broad healthcare technology (Primo Health) and specialized biotech venture development (Primo Biotech Lazio).
The regional partnership with Lazio indicates institutional support for innovation-focused venture capital development outside Italy's traditional VC hubs. By anchoring a dedicated biotech fund to a specific region, Primo Capital and the Lazio government have signaled commitment to building localized innovation capacity and talent retention in biotechnology. This approach aligns with broader European trends toward distributed venture capital networks that support emerging tech ecosystems beyond major financial centers.
Primo Capital's governance structure includes offices in Milan, Rome, and additional locations, with registration under Italy's FIA (fund manager) regulatory regime. The firm's multi-sector approach—evidenced by recent launches including Primo Space 2 (€120 million for European space technology) and Primo Digital (€62 million targeting approximately 25 companies in software and digital)—demonstrates a systematic strategy to deploy capital across high-growth technology segments. The Primo Biotech Lazio fund positions the firm to capture early-stage biotechnology opportunities while maintaining sector-specific expertise through dedicated management teams.
Primo Capital operates as a multi-fund investment vehicle with over €500 million in committed assets. The firm's investment strategy spans four primary sectors: digital, space, climate, and health. The Primo Biotech Lazio fund represents the company's targeted expansion into dedicated biotechnology investment, complementing its existing Primo Health fund, which focuses on healthcare technology and small-to-medium enterprises with a €120 million target. This structure allows Primo Capital to address the life sciences ecosystem through both broad healthcare technology (Primo Health) and specialized biotech venture development (Primo Biotech Lazio).
The regional partnership with Lazio indicates institutional support for innovation-focused venture capital development outside Italy's traditional VC hubs. By anchoring a dedicated biotech fund to a specific region, Primo Capital and the Lazio government have signaled commitment to building localized innovation capacity and talent retention in biotechnology. This approach aligns with broader European trends toward distributed venture capital networks that support emerging tech ecosystems beyond major financial centers.
Primo Capital's governance structure includes offices in Milan, Rome, and additional locations, with registration under Italy's FIA (fund manager) regulatory regime. The firm's multi-sector approach—evidenced by recent launches including Primo Space 2 (€120 million for European space technology) and Primo Digital (€62 million targeting approximately 25 companies in software and digital)—demonstrates a systematic strategy to deploy capital across high-growth technology segments. The Primo Biotech Lazio fund positions the firm to capture early-stage biotechnology opportunities while maintaining sector-specific expertise through dedicated management teams.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.